Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuda, Sayako, Fuji, Shigeo, Savani, Bipin, Gatwood, Katie S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492824/
https://www.ncbi.nlm.nih.gov/pubmed/36131129
http://dx.doi.org/10.1007/s44228-022-00012-8
_version_ 1784793561254854656
author Yuda, Sayako
Fuji, Shigeo
Savani, Bipin
Gatwood, Katie S.
author_facet Yuda, Sayako
Fuji, Shigeo
Savani, Bipin
Gatwood, Katie S.
author_sort Yuda, Sayako
collection PubMed
description Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV have been published, there is no detailed information about appropriate antiemetic drugs for each conditioning regimen in HSCT. Various studies reported that the triplet of 5-HT3RA, NK1RA, and dexamethasone appears useful in HSCT. However, each antiemetic has unique adverse effects or interactions with specific drugs. Here, we review the literature relating to clinical trials on the prevention of CINV, and summarize the information to clarify the benefit of antiemetic regimens.
format Online
Article
Text
id pubmed-9492824
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-94928242022-10-05 Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation Yuda, Sayako Fuji, Shigeo Savani, Bipin Gatwood, Katie S. Clin Hematol Int Review Article Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV have been published, there is no detailed information about appropriate antiemetic drugs for each conditioning regimen in HSCT. Various studies reported that the triplet of 5-HT3RA, NK1RA, and dexamethasone appears useful in HSCT. However, each antiemetic has unique adverse effects or interactions with specific drugs. Here, we review the literature relating to clinical trials on the prevention of CINV, and summarize the information to clarify the benefit of antiemetic regimens. Springer Netherlands 2022-07-11 /pmc/articles/PMC9492824/ /pubmed/36131129 http://dx.doi.org/10.1007/s44228-022-00012-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Yuda, Sayako
Fuji, Shigeo
Savani, Bipin
Gatwood, Katie S.
Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation
title Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation
title_full Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation
title_fullStr Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation
title_full_unstemmed Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation
title_short Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation
title_sort antiemetic strategies in patients who undergo hematopoietic stem cell transplantation
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492824/
https://www.ncbi.nlm.nih.gov/pubmed/36131129
http://dx.doi.org/10.1007/s44228-022-00012-8
work_keys_str_mv AT yudasayako antiemeticstrategiesinpatientswhoundergohematopoieticstemcelltransplantation
AT fujishigeo antiemeticstrategiesinpatientswhoundergohematopoieticstemcelltransplantation
AT savanibipin antiemeticstrategiesinpatientswhoundergohematopoieticstemcelltransplantation
AT gatwoodkaties antiemeticstrategiesinpatientswhoundergohematopoieticstemcelltransplantation

Ejemplares similares